93-O17S is a lipidoid used for generating lipid nanoparticles to deliver RNA, peptides, and nucleotides. 93-O17S LNPs were able to deliver Cre recombinase mRNA in mice. In addition, LNPs were able to deliver the Cre recombinase protein and Cas9:single-guide RNA into cells for genome editing. 93-O17S LNPs were used to deliver the STING pathway agonist 2′3′-Cyclic GMP-AMP (cGAMP) when injected into B16F10 tumors in mice which has potential as an in situ cancer vaccine.
|Molecular Weight (g/mol)||
-20 Â°C or below
1) Zhao X, Chen J, Qiu M, Li Y, Glass Z, Xu Q. (2020) “Imidazole-Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes.” Angew Chem Int Ed Engl. 59(45):20083-20089. doi: 10.1002/anie.202008082.
2) Li Y, Yang T, Yu Y, Shi N, Yang L, Glass Z, Bolinger J, Finkel IJ, Li W, Xu Q. (2018) “Combinatorial library of chalcogen-containing lipidoids for intracellular delivery of genome-editing proteins.” Biomaterials. 178:652-662. doi: 10.1016/j.biomaterials.2018.03.011.
3) Chen J, Qiu M, Ye Z, Nyalile T, Li Y, Glass Z, Zhao X, Yang L, Chen J, Xu Q. (2021) “In situ cancer vaccination using lipidoid nanoparticles.” Sci Adv. 7(19):eabf1244. doi: 10.1126/sciadv.abf1244.